On Market Share Buy Back
Filed with ASX · · 1 page · English
Summary by 6ix AI
The buy-back does not require shareholder approval as it falls within the limits set by the Corporations Act. The Board believes this program will enhance shareholder value while maintaining a strong balance sheet. The timing and total amount of shares purchased will depend on market conditions and the Board's assessment of capital management.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Australian Clinical Labs Ltd on 6ix
Story so far
Earlier from Australian Clinical Labs
- AIC proceedings - update
- Appendix 4E and Financial Report 30 June 2025
- FY25 Results Announcement
- FY25 Results Presentation
- Response to ASX Aware Letter
Later from Australian Clinical Labs
- ACL 1H26 financial results investor presentation
- Appendix 4D and 1H26 financial reports
- CEO contract update
- Class action proceedings
- Appointment of new Group CEO
Follow Australian Clinical Labs into a list and get an email when it puts out news.
Follow Australian Clinical Labs